The Institute for Clinical and Economic Review has identified five drugs — Biktarvy, Darzalex, Entresto, Cabometyx, and ...

小细胞肺癌 （SCLC） 是一种恶性程度高、侵袭性强的肺癌亚型，整体预后极差。据《中国肿瘤临床》，全球每年有超过20万例患者新发确诊SCLC，约占肺部恶性肿瘤总发病率的15%～20%，其中30%～40%处于局限期 （LS-SCLC） ...

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has ...

The FDA has approved the drug durvalumab for adults with limited-stage small-cell lung cancer (LS-SCLC) whose disease hasn’t gotten worse after getting platinum-based chemo and radiation at the same ...

AstraZeneca AZN announced that the FDA has accepted and granted priority review to its supplemental biologics license ...

AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended by NICE for treating adults with ...

A treatment for a rare type of cancer has been accepted for use on the NHS in Scotland. The Scottish Medicines Consortium ...

AstraZeneca’s Imfinzi (durvalumab) has been granted Priority Review by the FDA for the treatment of muscle-invasive bladder cancer (MIBC), pote ...

(IN BRIEF) AstraZeneca’s Imfinzi (durvalumab) has been granted Priority Review by the FDA for the treatment of muscle-invasive bladder cancer (MIBC), potentially becoming the first perioperative ...

Cambridge: AstraZeneca's supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab) has been accepted and ...

US FDA grants priority review status to AstraZeneca’s sBLA for Imfinzi to treat patients with muscle-invasive bladder cancer: Cambridge, UK Saturday, December 7, 2024, 09:00 Hrs ...

阿斯利康（AstraZeneca）宣布，其重磅免疫疗法Imfinzi（durvalumab）的补充生物制品许可申请（sBLA）已获美国FDA受理，并被授予优先审评资格，用于治疗肌层浸润性膀胱癌（MIBC）患者。FDA预计将在2025年第二季度对该申请 ...